Flamel Technologies Patent applications |
Patent application number | Title | Published |
20140072644 | ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM - The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. | 03-13-2014 |
20120308614 | COMPOSITION FOR THE CONTROLLED RELEASE OF BUPRENORPHINE - The present invention relates to a novel aqueous liquid pharmaceutical composition for the controlled release of buprenorphine or of an analogue of buprenorphine, comprising at least one prodrug with low aqueous solubility of said buprenorphine or analogue of buprenorphine, and at least one polymer having a linear backbone chosen from the polyglutamates, polyaspartates, poly(meth)acrylates and polysaccharides, to which one or more hydrophobic groups are grafted. | 12-06-2012 |
20120294832 | COMPOSITION COMPRISING INTERFERON ALPHA - The present invention relates to a novel solid composition, useful for treating hepatitis, in particular hepatitis C, comprising at least one interferon alpha and at least one grafted poly(glutamic acid) having an average molar mass ranging from 26,000 to 40,000 g/mol, preferably approximately 33,000 g/mol and carrying grafts of alpha-tocopherol at an average molar grafting rate ranging from 4.5 to 5.5%, preferably approximately 5%, the interferon alpha and said grafted poly(glutamic acid) being present in a grafted poly(glutamic acid)/interferon alpha weight ratio ranging from 21 to 125. | 11-22-2012 |
20120156257 | METHOD FOR THE PREPARATION OF NANOPARTICLES - The present invention relates to a novel method for the preparation of nanoparticles with a diameter smaller than or equal to 500 nm, comprising bringing a solution (1) comprising nanoparticles of a first polyelectrolyte in the charged state, bearing hydrophobic side groups, together with (2) at least one second polyelectrolyte of opposite polarity to that of the first polyelectrolyte, characterized in that the ratio Z of the number of cationic groups relative to the number of anionic groups in the mixture of the two polyelectrolytes is comprised between 0.1 and 0.75 or between 1.3 and 2; and the total mass concentration C of polyelectrolytes is strictly less than 2 mg/g of the mixture. | 06-21-2012 |
20120156256 | NANOPARTICLES HAVING AT LEAST ONE ACTIVE INGREDIENT AND AT LEAST TWO POLYELECTROLYTES - The present invention relates to novel nanoparticles formed by at least one active ingredient and by at least two polyelectrolytes of opposite polarity, in particular characterized in that at least one of the two polyelectrolytes bears hydrophobic side groups and at least one of the two polyelectrolytes bears side groups of the polyalkylene glycol type, said nanoparticles having an average diameter ranging from 10 to 100 nm and comprising a quantity of groups of the polyalkylene glycol type such that the mass ratio w | 06-21-2012 |
20110150837 | Amphiphilic polymer functionalized by methionine - The present invention relates to new amphiphilic polymers comprising hydrophobic groups and methionine groups. | 06-23-2011 |
20110129540 | Polymer of acrylic or methacrylic type comprising alpha-tocopherol grafts - The present invention relates to a novel family of polymers of acrylic and/or methacrylic type, comprising alpha-tocopherol grafts, capable of forming nanoparticles in an aqueous medium at a neutral pH. | 06-02-2011 |
20110129539 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AN AQUEOUS SUSPENSION OF MICROCAPSULES FOR MODIFIED RELEASE OF AMOXICILLIN - The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of amoxicillin and consisting of suspensions of coated particles of amoxicillin (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed, according to the invention, to enable modified release of amoxicillin, in accordance with a profile which remains unaltered during the shelf life of the liquid suspension. Therefor, the invention consists in selecting a coating composition specific to the microcapsules consisting of at least four components enabling preservation of said microcapsules in water without altering their properties of modified release of amoxicillin, said liquid phase being furthermore saturated with amoxicillin. | 06-02-2011 |
20110117205 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AQUEOUS SUSPENSION FOR MODIFIED RELEASE OF ACTIVE PRINCIPLE(S) - The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s). | 05-19-2011 |
20110104266 | MULTIMICROPARTICULATE PHARMACEUTICAL FORMS FOR ORAL ADMINISTRATION - The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. | 05-05-2011 |
20110091537 | Anti-misuse solid oral pharmaceutical form provided with a specific modified release profile - The present invention relates to a solid oral pharmaceutical form, with modified release of at least one active ingredient, containing at least microparticles containing said active ingredient and at least one viscosifying agent in a form isolated from said microparticles of active ingredient, characterized in that said microparticles possess an average diameter ranging from 100 to 600 μm, and are formed by a core containing at least said active ingredient and coated with at least one coating layer,
| 04-21-2011 |
20100310667 | CONTROLLED-RELEASE FLOATING PHARMACEUTICAL COMPOSITIONS - The invention relates to a pharmaceutical composition comprising a plurality of controlled-release coated microparticles each comprising a floating core, on the surface of which is deposited a layer containing at least one active principle, said layer being covered with a controlled-release coating, characterized by the fact that said floating core is composed of cellulose acetate phthalate and has an apparent density of less than or equal to 0.6 g/mL and said coated microparticles have a density of less than or equal to 0.7 g/mL. | 12-09-2010 |
20100178337 | Composition comprising an active agent with low aqueous solubility - The present invention relates to a composition comprising at least one active ingredient with low aqueous solubility, said active ingredient being present therein in a form noncovalently associated with nanoparticles formed by at least one POM polymer of formula (I), and in which said active ingredient is present in a proportion of at least 5 μmol/g of POM. | 07-15-2010 |
20100098656 | Polyamino acids functionalized by hydrophobic grafts bearing an anionic charge and applications thereof, such as therapeutic applications - The present invention relates to novel materials based on biodegradable polyamino acids that are useful especially for the vectorization of active principle(s) (AP). The invention further relates to novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on these polyamino acids. The object of the invention is to provide a novel polymer starting material that is capable of being used for the vectorization of AP and makes it possible on the one hand to achieve high polymer/AP ratios, and on the other hand optimally to satisfy all the specifications required in the case in point: biocompatibility, biodegradability, ability to associate easily with numerous active principles or to solubilize them, and ability to release these active principles in vivo. This object is achieved by the present invention, which relates first and foremost to linear polyamino acids comprising aspartic units or glutamic units and having hydrophobic grafts comprising hydrophobic groups containing from 8 to 30 carbon atoms, at least one of these hydrophobic grafts having at least one anionic charge and/or one or more mutually identical or different ionizable groups each capable of giving rise to at least one anionic charge. These polymers are amphiphilic and anionic and are capable of being converted easily and economically to particles for the vectorization of active principles, these particles themselves being capable of forming stable aqueous colloidal suspensions. | 04-22-2010 |
20100092553 | ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM - The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. | 04-15-2010 |
20090110742 | Long-acting colloidal insulin formulation and its preparation - The invention relates to injectable long-acting insulin formulations for the treatment of types I and II diabetes in humans and animals. | 04-30-2009 |
20080305160 | Oral Medicament For The Modified Release Of At Least One Active Principle, In Multimicrocapsule Form - The field of the invention is that of oral medicaments or pharmaceutical compositions, in particular of the type including one or more active principles. The aim of the invention is to provide an improved oral medicament to be administered in one or several daily doses and enabling the modified release of active principles (in particular of one active principle), whereby the prophylactic and therapeutic effectiveness of said medicament is improved. This aim is achieved by the oral multimicrocapsule galenic form according to the invention, in which the active principle release is controlled by a dual release trigger mechanism: “time-dependent trigger” and “pH-dependent trigger”. Said medicament includes microcapsules providing the modified release of the active principle, each comprising a core containing | 12-11-2008 |
20080260844 | Solid, Oral, Microparticulate Dosage Form Which Has Been Designed To Prevent Misuse - The invention relates to the field of solid, oral, microparticulate dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient contained therein. The aim of the invention is to prevent the improper use of solid oral medicaments for any use other than the therapeutic use(s) officially approved by the appropriate public health authorities. More specifically, the invention relates to a solid, oral drug form which is characterised in that at least one part of the active pharmaceutical ingredient is contained in the microparticles thereof and in that the inventive form comprises anti-crushing means which are intended to impede or completely prevent the crushing of the microparticles of the active pharmaceutical ingredient, such as to preclude the misuse thereof. | 10-23-2008 |